Page last updated: 2024-12-11
pseudobactin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pseudobactin: linear hexapeptide fluorescent iron transport agent (siderophore) from plant growth promoter Pseudomonas B10; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5486206 |
| SCHEMBL ID | 407362 |
| MeSH ID | M0102681 |
Synonyms (12)
| Synonym |
|---|
| pseudobactin |
| (2r,3r)-3-[[(2s)-2-amino-6-[[(1s)-5-[(4-amino-4-oxobutanoyl)amino]-8-hydroxy-9-oxo-1,2,3,4-tetrahydropyrimido[1,2-a]quinoline-1-carbonyl]amino]hexanoyl]amino]-2-hydroxy-4-[[(2s)-1-[[(2r,3r)-3-hydroxy-1-[[(2s)-1-[[(3r)-1-hydroxy-2-oxopiperidin-3-yl]amino]- |
| l-alaninamide, n6-(((1s)-5-((4-amino-1,4-dioxobutyl)amino)-2,3-dihydro-8,9-dihydroxy-1h-pyrimido(1,2-a)quinolin-1-yl)carbonyl)-l-lysyl-(3r)-3-hydroxy-d-alpha-aspartyl-l-alanyl-d-allothreonyl-n-((3r)-1-hydroxy-2-oxo-3-piperidinyl)- |
| ferric pseudobactin |
| 9w6vy0jkdk , |
| unii-9w6vy0jkdk |
| 76975-04-7 |
| l-alaninamide, n6-((5-((4-amino-1,4-dioxobutyl)amino)-2,3-dihydro-8,9-dihydroxy-1h-pyrimido(1,2-a)quinolin-1-yl)carbonyl)-l-lysyl-threo-3-hydroxy-d-alpha-aspartyl-l-alanyl-d-allothreonyl-n-(1-hydroxy-2-oxo-3-piperidinyl)-, (1(s),5(r))- |
| l-alaninamide, n6-(((1s)-5-((4-amino-1,4-dioxobutyl)amino)-2,3-dihydro-8,9-dihydroxy-1h-pyrimido(1,2-a)quinolin-1-yl)carbonyl)-l-lysyl-(3r)-3-hydroxy-d-.alpha.-aspartyl-l-alanyl-d-allothreonyl-n-((3r)-1-hydroxy-2-oxo-3-piperidinyl)- |
| SCHEMBL407362 |
| Q27273303 |
| AKOS040753641 |
Research Excerpts
Overview
Pseudobactin is a structurally complex and physiologically important siderophore (microbial iron chelator) from Pseudomonas putida-fluorescens.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pseudobactin is a structurally complex and physiologically important siderophore (microbial iron chelator] from Pseudomonas putida-fluorescens. " | ( Synthesis of fragments of the peptide component of pseudobactin. Kolasa, T; Miller, MJ; Okonya, JF, ) | 1.83 |
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pseudobactin P39167-I has a molecular formula of C46H65O23N13 and is monoanionic at neutral pH." | ( Structures and characteristics of novel siderophores from plant deleterious Pseudomonas fluorescens A225 and Pseudomonas putida ATCC 39167. Gross, ML; Khalil-Rizvi, S; Toth, SI; van der Helm, D; Vidavsky, I, 1997) | 1.02 |
| "Pseudobactin P39167-I has a molecular formula of C46H65O23N13 and is monoanionic at neutral pH." | ( Structures and characteristics of novel siderophores from plant deleterious Pseudomonas fluorescens A225 and Pseudomonas putida ATCC 39167. Gross, ML; Khalil-Rizvi, S; Toth, SI; van der Helm, D; Vidavsky, I, 1997) | 1.02 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (26)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (23.08) | 18.7374 |
| 1990's | 15 (57.69) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.45
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.45) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (3.57%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 27 (96.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||